A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer

Author: Miller Brigitte  

Publisher: Informa Healthcare

ISSN: 1473-3404

Source: The Women's Oncology Review, Vol.4, Iss.1, 2004-01, pp. : 29-30

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content